Fed. Circ. Wipes Out $1.1B Juno IP Win On Cancer Drug

By Britain Eakin (August 26, 2021, 12:25 PM EDT) -- The Federal Circuit on Thursday reversed a $1.1 billion judgment against Gilead's Kite Pharma Inc. for infringing Bristol-Myers cancer immunotherapy patent, ruling that the patent is invalid because it lacks adequate written description support....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!